Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Exelixis, Inc.
Armed with an old drug and new data, the group is aiming to revitalize the smoking cessation market.
Two days after FDA advisory panel’s meeting to discuss whether oral phenylephrine is effective for nasal congestion, complaints filed in federal court in multiple states alleging manufacturers knowingly misled public about ingredient’s efficacy. FDA’s potential response to NDAC’S finding wouldn’t come as soon.
After feeling the heat from activist investor Farallon Capital Management earlier this year, CEO Michael Morrissey has defended its spending on in-house R&D and in-licensing as it announced a new oncology deal.
CMS has not disclosed how many requests for the exception it received but will follow up with applicants regarding its decisions this month.
- Other Names / Subsidiaries
- X-Ceptor Therapeutics, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.